Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02786732 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate Broadlumab vs Placebo and Ustekinumab
A Phase 3 study, sponsored by MedDerm Associates.
- Terminated
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT02786732: Clinical Trial Phase 3 study, sponsored by MedDerm Associates.
NCT02786732 is a Phase 3 study that was terminated before completion, run by MedDerm Associates. The registered enrollment target is 15 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02786732, a Phase 3 study, was terminated before completion, sponsored by MedDerm Associates.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Ustekinumab
- BIOLOGICAL 210mg Brodalumab
- BIOLOGICAL 140mg Brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-08 |
| Est. Completion | 2017-10 |
| Phase | Phase 3 |
Why NCT02786732 stopped before completion
NCT02786732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02786732 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02786732 about?
NCT02786732 is a clinical study titled "Study to Evaluate Broadlumab vs Placebo and Ustekinumab". The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.
What is the current status of trial NCT02786732?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2012-08. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02786732?
The interventions under investigation include: Placebo (BIOLOGICAL), Ustekinumab (BIOLOGICAL), 210mg Brodalumab (BIOLOGICAL), 140mg Brodalumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02786732?
This trial is sponsored by MedDerm Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02786732's enrollment target sits among peer trials
15 1977th of 2000 higher than 18 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia